当前位置: 首页 >> 检索结果
2361. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
作者: Sanjay Rajagopalan.;Emile R Mohler.;Robert J Lederman.;Farrell O Mendelsohn.;Jorge F Saucedo.;Corey K Goldman.;John Blebea.;Jennifer Macko.;Paul D Kessler.;Henrik S Rasmussen.;Brian H Annex.
来源: Circulation. 2003年108卷16期1933-8页
"Therapeutic angiogenesis" seeks to improve perfusion by the growth of new blood vessels. The Regional Angiogenesis with Vascular Endothelial growth factor (RAVE) trial is the first major randomized study of adenoviral vascular endothelial growth factor (VEGF) gene transfer for the treatment of peripheral artery disease (PAD).
2362. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
作者: Ron J G Peters.;Shamir R Mehta.;Keith A A Fox.;Feng Zhao.;Basil S Lewis.;Steven L Kopecky.;Rafael Diaz.;Patrick J Commerford.;Vicent Valentin.;Salim Yusuf.; .
来源: Circulation. 2003年108卷14期1682-7页
We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS).
2363. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
作者: Scott Kinlay.;Gregory G Schwartz.;Anders G Olsson.;Nader Rifai.;Sally J Leslie.;William J Sasiela.;Michael Szarek.;Peter Libby.;Peter Ganz.; .
来源: Circulation. 2003年108卷13期1560-6页
Inflammation promotes acute coronary syndromes and ensuing clinical complications. Although statins reduce inflammatory markers in asymptomatic adults or in patients with stable angina, the effect of statins on the markedly heightened inflammation in patients with acute coronary syndromes is unknown.
2364. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial.
作者: Zefeng Zhang.;Elizabeth M Mahoney.;Rodney H Stables.;Jean Booth.;Fiona Nugara.;John A Spertus.;William S Weintraub.
来源: Circulation. 2003年108卷14期1694-700页
Functional status and quality of life are important outcomes in the evaluation of revascularization approaches for symptomatic coronary artery disease. Few data are available regarding the comparative improvement in disease-specific health status after CABG versus percutaneous coronary intervention (PCI) in the era of coronary stenting.
2365. Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation: the Atrial Fibrillation Suppression Trial II (AFIST II).
作者: C Michael White.;Michael F Caron.;James S Kalus.;Heidi Rose.;Jessica Song.;Prabashni Reddy.;Robert Gallagher.;Jeffrey Kluger.; .
来源: Circulation. 2003年108 Suppl 1卷II200-6页
The effect of a hybrid intravenous and oral prophylactic amiodarone regimen on postcardiothoracic surgery (CTS) atrial fibrillation (AF) is unknown. The impact of active atrial septal pacing on post-CTS AF has not been well characterized. In addition, the effect of using both amiodarone and atrial septal pacing together to prevent atrial fibrillation is unknown.
2366. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement.
作者: H Koertke.;K Minami.;D Boethig.;Th Breymann.;D Seifert.;O Wagner.;N Atmacha.;A Krian.;J Ennker.;U Taborski.;W P Klövekorn.;R Moosdorf.;W Saggau.;R Koerfer.
来源: Circulation. 2003年108 Suppl 1卷II75-8页
The Early Self Controlled Anticoagulation Trial (ESCAT I) showed that anticoagulation self-management after mechanical heart valve replacement decreased complication rates by maintaining INR levels closer to the target range than International Normalized Ratio (INR) home doctor management. The therapeutic range for the INR in that study was between 2.5 and 4.5 for all positions of prosthetic valves. ESCAT II should find out whether lowering the target range for INR self-management would further reduce complication rates.
2367. Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery.
作者: Claudio Muneretto.;Gianluigi Bisleri.;Alberto Negri.;Jacopo Manfredi.;Marco Metra.;Savina Nodari.;Lidia Culot.;Livio Dei Cas.
来源: Circulation. 2003年108 Suppl 1卷II29-33页
Total arterial myocardial revascularization with composite grafts proved to enhance the long-term benefits of coronary surgery. We assessed the hypothesis that full arterial revascularization (FAR) may improve clinical outcome even in elderly and at short term.
2368. Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II Study.
作者: Desiderio Favarato.;Whady Hueb.;Bernard J Gersh.;Paulo R Soares.;Luiz A M Cesar.;Protásio L da Luz.;Sergio A Oliveira.;Jose A F Ramires.; .
来源: Circulation. 2003年108 Suppl 1卷II21-3页
Prior comparisons of costs following CABG and PTCA have demonstrated higher initial costs after CABG but following PTCA, recurrent symptoms and repeat revascularization result in increased late costs and over time their costs equilibrate. The MASS II trial provides an opportunity to compare the costs of CABG and PTCA in addition to a strategy of medical therapy.
2369. Attenuation of nitrate tolerance and oxidative stress by an angiotensin II receptor blocker in patients with coronary spastic angina.
作者: Nobutaka Hirai.;Hiroaki Kawano.;Hirofumi Yasue.;Hideki Shimomura.;Shinzo Miyamoto.;Hirofumi Soejima.;Ichiro Kajiwara.;Tomohiro Sakamoto.;Michihiro Yoshimura.;Hajime Nakamura.;Junji Yodoi.;Hisao Ogawa.
来源: Circulation. 2003年108卷12期1446-50页
Nitrates are widely used to treat coronary artery disease, but their therapeutic value is compromised by the rapid development of tolerance. Recently, the renin-angiotensin system has been suggested to play an important role in the development of nitrate tolerance.
2370. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
Cholesterol modification reduces cardiovascular events in patients with atherosclerosis, including those with peripheral arterial disease. The purpose of this study was to determine whether cholesterol lowering with atorvastatin improves walking performance in patients with intermittent claudication.
2371. Impact of preinterventional arterial remodeling on neointimal hyperplasia after implantation of (non-polymer-encapsulated) paclitaxel-coated stents: a serial volumetric intravascular ultrasound analysis from the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT).
作者: Gary S Mintz.;Adrienne Tinana.;Myeong-Ki Hong.;Cheol Whan Lee.;Jae-Joong Kim.;Neal E Fearnot.;Seong-Wook Park.;Seung-Jung Park.;Neil J Weissman.
来源: Circulation. 2003年108卷11期1295-8页
This study used serial volumetric intravascular ultrasound (IVUS) to evaluate the effect of preinterventional arterial remodeling on in-stent intimal hyperplasia (IH) after implantation of non-polymer-encapsulated paclitaxel-coated stents.
2372. Differences in medical care and disease outcomes among black and white women with heart disease.
作者: Ashish K Jha.;Paul D Varosy.;Alka M Kanaya.;Donald B Hunninghake.;Mark A Hlatky.;David D Waters.;Curt D Furberg.;Michael G Shlipak.
来源: Circulation. 2003年108卷9期1089-94页
The risk of cardiovascular mortality is higher among black women than white women, and the reasons for this disparity are largely unexplored. We sought to evaluate differences in medical care and clinical outcomes among black and white women with established coronary artery disease.
2373. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.
作者: Tobias Kurth.;Robert J Glynn.;Alexander M Walker.;K Arnold Chan.;Julie E Buring.;Charles H Hennekens.;J Michael Gaziano.
来源: Circulation. 2003年108卷10期1191-5页
There is clear evidence from numerous randomized trials and their meta-analyses that aspirin reduces risks of first myocardial infarction (MI). Recent data also suggest that other nonsteroidal anti-inflammatory drugs (NSAIDs) may interfere with this benefit of aspirin.
2374. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
作者: James E Tcheng.;David E Kandzari.;Cindy L Grines.;David A Cox.;Mark B Effron.;Eulogio Garcia.;John J Griffin.;Giulio Guagliumi.;Thomas Stuckey.;Mark Turco.;Martin Fahy.;Alexandra J Lansky.;Roxana Mehran.;Gregg W Stone.; .
来源: Circulation. 2003年108卷11期1316-23页
Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary percutaneous coronary intervention for acute myocardial infarction (MI) have shown improved early clinical and angiographic outcomes with treatment. However, variations in trial designs, modest sample sizes, and limited long-term follow-up have precluded these studies from being definitive.
2375. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte.
作者: Uwe Zeymer.;Rainer Uebis.;Albrecht Vogt.;Hans-Georg Glunz.;Hans-Friedrich Vöhringer.;Dietrich Harmjanz.;Karl-Ludwig Neuhaus.; .
来源: Circulation. 2003年108卷11期1324-8页
Percutaneous transluminal coronary angioplasty of the infarct-related artery in stable survivors of acute myocardial infarction is often performed, even in patients without any symptoms or residual ischemia. Despite the lack of randomized studies, it is widely believed that this intervention will improve the clinical outcome of these patients.
2376. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
作者: Jay N Cohn.;Inder S Anand.;Roberto Latini.;Serge Masson.;Yann-Tong Chiang.;Robert Glazer.; .
来源: Circulation. 2003年108卷11期1306-9页
Aldosterone has been implicated in the progression of heart failure. The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure.
2377. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis.
作者: Albert Schömig.;Gjin Ndrepepa.;Julinda Mehilli.;Markus Schwaiger.;Helmut Schühlen.;Stephan Nekolla.;Jürgen Pache.;Stefan Martinoff.;Hildegard Bollwein.;Adnan Kastrati.
来源: Circulation. 2003年108卷9期1084-8页
The relationship between myocardial salvage and time-to-treatment interval in patients with acute myocardial infarction (AMI) treated with coronary artery stenting or thrombolysis has not been studied.
2378. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
作者: Kenneth W Mahaffey.;Christopher B Granger.;Jose C Nicolau.;Witold Ruzyllo.;W Douglas Weaver.;Pierre Theroux.;Judith S Hochman.;Thomas G Filloon.;Christopher F Mojcik.;Thomas G Todaro.;Paul W Armstrong.; .
来源: Circulation. 2003年108卷10期1176-83页
Complement activation mediates myocardial damage that occurs during ischemia and reperfusion through multiple pathways. We performed 2 separate, parallel, double-blind, placebo-controlled trials to determine the effects of pexelizumab (a novel C5 complement monoclonal antibody fragment) on infarct size in patients receiving reperfusion therapy: COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) and COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA). The COMPLY trial is reported here.
2379. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
作者: Christopher B Granger.;Kenneth W Mahaffey.;W Douglas Weaver.;Pierre Theroux.;Judith S Hochman.;Thomas G Filloon.;Scott Rollins.;Thomas G Todaro.;Jose C Nicolau.;Witold Ruzyllo.;Paul W Armstrong.; .
来源: Circulation. 2003年108卷10期1184-90页
Complement, activated during myocardial ischemia and reperfusion, causes myocardial damage through multiple processes. The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial was performed to determine the effect of pexelizumab, a C5 complement inhibitor, on infarct size in patients with ST-segment-elevation myocardial infarction (MI) undergoing primary percutaneous coronary intervention.
2380. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
作者: Jacqueline Saw.;Steven R Steinhubl.;Peter B Berger.;Dean J Kereiakes.;Victor L Serebruany.;Danielle Brennan.;Eric J Topol.; .
来源: Circulation. 2003年108卷8期921-4页
Statins primarily metabolized by cytochrome P450 3A4 (CYP3A4) reportedly reduce clopidogrel's metabolism to active metabolite, thus attenuating its inhibition of platelet aggregation ex vivo. However, the clinical impact of this interaction has not been evaluated.
|